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Abstract
Background: Nonalcoholic steatohepatitis (NASH), a progressive stage of nonalcoholic fatty liver disease (NAFLD),
is characterized by steatosis (accumulation of triacylglycerols within hepatocytes) along with inflammation and
ballooning degeneration. It has been suggested that oxidative stress may play an important role in the progress of
NAFLD to NASH. The aim of present study was to determine whether antioxidant supplementations using EUK-8,
EUK-134 and vitamin C could improve the biochemical and histological abnormalities associated with diet-induced
NASH in rats.
Methods: NASH was induced in male N-Mary rats by feeding a methionine - choline deficient (MCD) diet. The rats
were fed either normal chow or MCD diet for 10 weeks. After NASH development, the MCD-fed rats were
randomly divided into four groups of six: the NASH group that received MCD diet, the EUK-8 group which was fed
MCD diet plus EUK-8, the EUK-134 group which was fed MCD diet plus EUK-134 and the vitamin C group which
received MCD diet plus vitamin C. EUK-8, EUK-134 and vitamin C (30 mg/kg body weight/day) were administered
by gavage for eight weeks.
Results: Treatment of MCD-fed rats with salens reduced the sera aminotransferases, cholesterol, low density
lipoprotein contents, the extent of lipid peroxidation and protein carbonylation whereas the HDL-C cholesterol
levels were significantly increased. In addition, EUK-8 and EUK-134 improved steatosis, ballooning degeneration and
inflammation in liver of MCD-fed rats.
Conclusion: Antioxidant (EUK-8, EUK-134 and vitamin C) supplementation reduces NASH-induced biochemical and
histological abnormalities, pointing out that antioxidant strategy could be beneficial in treatment of NASH.
Keywords: Nonalcoholic fatty liver, superoxide dismutase mimetic, oxidative stress, Mn-salen complexes, methio-
nine and choline deficient diet
Background
Nonalcoholic fatty liver disease (NAFLD) is regarded as
a hepatic manifestation of the metabolic syndrome
which is associated with obesity, insulin resistance, dysli-
pidemia and hypertension [1]. NAFLD encompasses a
spectrum of liver abnormalities, including simple steato-
sis (nonalcoholic fatty liver, NAFL), nonalcoholic steato-
hepatitis (NASH), fibrosis and cirrhosis [2]. NAFLD is
defined as hepatic fat accumulation exceeding 5-10% of
liver weight, in the absence of excess alcohol
consumption or any other liver disease and other causes
of steatosis, such as certain toxins and drugs [2,3]. It is
estimated that NAFLD affects 20-30% of the general
population, 20-30% of which eventually progress into
NASH. As a progressive stage of NAFLD, NASH is
characterized by steatosis (accumulation of triacylglycer-
ols within hepatocytes) along with inflammation and
ballooning degeneration. The pathogenesis of steatosis
occurrence and progression of NAFLD into NASH are
not fully understood. A “multi-hit” (previously called “
two-hit”) hypothesis has been proposed to explain the
progression of NAFLD into NASH [4]. It is believed
that insulin resistance and/or prolonged over-nutrition
* Correspondence: yazdan@ibb.ut.ac.ir
1Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran
Full list of author information is available at the end of the article
Rezazadeh et al. Journal of Biomedical Science 2012, 19:26
http://www.jbiomedsci.com/content/19/1/26
© 2012 Rezazadeh et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.leads to steatosis (first hit), which sensitizes the hepa-
tocytes to other factors such as oxidative stress, cyto-
kine/adipokine interplay and mitochondrial injury,
eventually leading to the development of NASH [2,4].
Insulin resistance is caused by genetic and acquired
factors (such as obesity, pregnancy, inactive lifestyle,
etc.). Possibly, there is a link between oxidative stress
and insulin resistance.
The incidence of oxidative stress has been reported to
be high among patients with metabolic syndrome and
NASH [5,6]. In these patients, superoxide dismutase
activity, the serum vitamin C and a-tocopherol concen-
trations are low, whereas lipid peroxidation and protein
carbonylation levels are high [7]. Lipid peroxidation pro-
ducts initiate chemical modification of many biological
molecules and also they participate in signal transduc-
tion of many inflammatory responses with up-regulation
of pro-inflammatory cytokines, such as TNF-a, IL-6 and
IL-1. TNF-a in turn induces NADPH oxidase that leads
to inflammation [8]. The involvement of oxidative stress
in the pathogenesis of NASH, suggests that antioxidants
might have beneficial effects in the treatment of NASH
patients [7]. It has been shown that antioxidant drugs
improve insulin resistance in the metabolic syndrome
models. For instance, antioxidant vitamin (vitamins C
and E) therapies of diabetic patients had improving
effects on insulin resistance [8]. Antioxidant enzymes [e.
g. superoxide dismutase (SOD) and catalase] protect
cells against oxidative damage. However, the application
of proteinaceous antioxidant enzymes might clinically be
an inefficient approach due to enzyme instability and
the high cost and thus, this approach has limited appli-
cation [9]. On the other hand, the use of synthetic anti-
oxidant enzyme mimetics might prove to be an ideal
alternative approach for antioxidant therapy. To date,
several types of SOD mimics have been evaluated using
various experimental models of oxidative stress [10].
The Mn-salen complexes [salen = bis(salicylaldehyde)
ethylenediamine], are amongst these mimetics. These
low-molecular-weight synthetic compounds exhibit
SOD, catalase and peroxidase activities [11]. The
mechanism for the catalase activity of Mn-salen involves
the oxidation of Mn(III) to oxomanganese by H2O2,
releasing water. The oxomanganese is then reduced to
Mn(III) by another hydrogen peroxide molecule to form
oxygen and water. The mechanism by which each Mn-
salen complex acts as a superoxide dismutase mimetic
involves the reduction of Mn(III) to Mn(II) by O2
-·
resulting in production of O2. The Mn(II) is oxidized
back to Mn(III) by another molecule of O2
-· yielding
H2O2 [12]. The protective effects of these antioxidants
against oxidative stress-induced injuries have been
reported in many in vitro and in vivo disease models,
including, stroke, amyotrophic lateral sclerosis,
Parkinson [13], excitotoxic neuronal injury [14] and
adult respiratory distress syndrome [15].
Here, we report the effects of two Mn-salen com-
plexes EUK-8 and EUK134 (Figure 1) on the treatment
of NASH, induced by feeding rats a diet deficient in
methionine and choline (MCD). We found that EUK-8
and EUK-134 treatments effectively normalized the
indices of the oxidative stress, decreased the sera marker
enzyme activities and also improved the liver
morphology.
Methods
Materials
Bovine serum albumin (BSA), reduced nicotinamide
adenine dinucleotide (NADH), reduced nicotinamide
adenine dinucleotide phosphate (NADPH), ascorbic
a c i d ,5 ,5 ’-dithiobisnitro benzoic acid (DTNB), nitro-
blue tetrazolium (NBT), hydrogen peroxide (H2O2)
and thiobarbituric acid (TBA) were obtained from
Merck Co. (Darmstadt, Germany). Reduced and oxi-
dized glutathione were obtained from Fluka (Buchs,
Switzerland). Glutathione reductase (GR) was obtained
from Sigma-Aldrich Chemical Co. Ltd. (Gillingham,
England). Trichloroacetic acid (TCA), 2, 4-dinitrophe-
nylhydrazine (DNPH) and Folin-Ciocalteu reagent
were obtained from Sigma (St. Louis, MO, USA). All
other chemicals were of analytical grade. Mn-salen
compounds, EUK-8 and EUK-134, were synthesized as
described by Baker et al. [16] and stored within a
desiccator. Fresh solution of each Mn-salen was pre-
pared in water as required.
Animals, diets and drug treatments
Animal procedures were approved by the Ethics Com-
mittee of University of Tehran. Male N-marry rats (250-
300 g) were obtained from Pasteur institute (Tehran,
Iran). The rats were fed either normal chow or the
MCD diet [17] for 10 weeks. After NASH development,
Figure 1 Chemical structures of the Mn-salen complexes EUK-8
and EUK-134.
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groups: the NASH group (n = 6) that received MCD
diet, the EUK-8 group (n = 6) which was fed MCD
diet plus EUK-8, the EUK-134 group (n = 6) which
was fed MCD diet plus EUK-134 and the vitamin C
g r o u p( n=6 )w h i c hr e c e i v e dM C Dd i e tp l u sv i t a m i n
C. The antioxidants, EUK-8, EUK-134 and vitamin C
(30 mg/kg body weight/day) were administered orally
for eight weeks. The Mn-salen derivatives were dis-
solved in double-distilled water and the NASH and the
control groups received water as the vehicle. After
eight weeks, the rats were sacrificed after an overnight
fast, under diethyl ether anesthesia and the livers were
rapidly removed and weighed. A portion of each liver
was fixed in 10% formalin solution for histopathologi-
cal examination and the remainder was snap-frozen for
later analyses. All rats were weighed at the start of the
experiment and before sacrifice to record the body
weight variations.
Assessment of steatohepatitis
Fresh liver tissue samples were kept in 10% formalin
solution and paraffin blocks were subsequently prepared.
Paraffin-embedded liver sections were stained with
hematoxylin-eosin and Masson-trichrome. All specimens
were evaluated blindly by an expert pathologist, using
the scoring system proposed by Kleiner et al. [18]: stea-
tosis (0-3), lobular inflammation (0-3) and ballooning
degeneration (0-2). Fibrosis was minimal in all samples
and was therefore not scored.
Liver homogenate preparation
Each liver sample was homogenized in phosphate buffer
(50 mM, pH 7.5) to obtain a 10% (w/v) liver homoge-
nate. The homogenate was then centrifuged at 5000 ×g
for 15 min at 4°C. Each supernatant was collected into 1
ml aliquots and stored at -70°C until use. The protein
content of each sample was determined using Lowry
method [19] and bovine serum albumin as the standard.
Biochemical assays
The sera were separated by centrifugation at 4°C and
stored at -20°C. The sera levels of total cholesterol (TC),
high density lipoprotein cholesterol (HDL-C), triglycer-
ides (TG), fasting blood glucose (FBG) and albumin
were measured using commercially available kits (Pars
Azmun, Tehran, Iran).
Serum markers of hepatic damage
The sera activity of alkaline phosphatase (ALP), alanine
aminotransferase (ALT), aspartate aminotransferase
(AST) and gamma-glutamyl transferase (GGT), as some
of the damage markers, were measured using commer-
cially available kits (Pars Azmun, Tehran, Iran).
Antioxidant enzyme assays
The liver superoxide dismutase activity was measured
based on the inhibition of amino blue tetrazolium for-
mazan formation in a reaction mixture composed of
NADH, phenazine methosulfate (PMS) and nitroblue
tetrazolium (NBT) [20]. The color intensity was mea-
sured using a spectrophotometer (VARIAN CARY 100
Conc, USA) at 560 nm. One unit of SOD is defined as
the amount of protein that inhibits the rate of NBT
reduction by 50%.
The catalase activity was measured by spectrophoto-
metric analysis of the decomposition rate of hydrogen
peroxide at 240 nm. The activity for H2O2 decomposi-
tion was expressed as k.s
-1mg
-1 protein, where k is the
first-order rate constant [20].
Hepatic markers of oxidative stress
Hepatic lipid peroxidation was determined using thio-
barbituric acid reactive substances (TBARS) for the esti-
mation of malondialdehyde (MDA) content. The
absorbance was measured at 532 nm with respect to the
blank solution. The concentration of TBARS was then
calculated using an extinction coefficient of 155 (cm
-1
mM
-1) for the TBARS/MDA complex [21].
Protein carbonyl (PCO) content was estimated using
the 2, 4-dinitrophenylhydrazine (DNPH)-based proce-
dure. The absorbance of each sample was measured at
320 nm and the tissue protein carbonyl content was cal-
culated based on the molar extinction coefficient of
DNPH (2.2 × 10
4 cm
-1 M
-1) [22].
Statistical analyses
All data were expressed as mean ± standard deviation
(SD) and statistical significance of the differences
between groups was assessed using Student’st - t e s t .A
level of P < .05 was regarded as statistically significant.
Results
Weight and liver index
The rats in NASH group showed a 12% decrease in
body weight, but those in the normal diet group
increased weight by 17%, whereas the body weights of
the groups on EUK-8, EUK-134 and vitamin C
increased by 10%, 15% and 8%, respectively. In con-
trast, the liver index [the percentage of wet liver
weight to body weight (g)], reduced by EUK-8, EUK-
134 and vitamin C treatments in MCD-fed group by
13%, 12% and 7%, respectively relative to drug -
untreated MCD-fed rats (Table 1).
Histopathological analyses
The histological studies of the liver samples from the
control and the test groups were performed to investi-
gate the occurrence of steatohepatitis. Treatment of
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significant effects on the grade of NASH among MCD-
f e dr a t s( T a b l e2 ) .B a s e do nF igure 2, the liver samples
of the control animals showed no evidences of steatosis,
inflammation or fibrosis (Figure 2A), the NASH group
showed grade two liver steatosis, inflammation and bal-
looning degeneration. Furthermore, no incidence of
fibrosis was recorded among the control and the MCD-
fed rats (Figure 2, B and 2F). Normal liver architecture
without the incidence of steatosis and inflammation was
observed in EUK-8-treated rats (Figure 2C). Similar
results were observed in EUK-134 group (Figure 2D).
Among the vitamin C-treated rats however, focal macro-
vesicular steatosis without inflammation, were evident as
shown in Figure 2E.
Sera biochemical evaluations
Biochemical analyses of the sera were performed to
document any possible changes in albumin, FBG and
lipid profile of the control and the test animals. As
Table 1 Phenotypic and biochemical parameters.
Control NASH MCD+EUK-8 MCD+EUK-134 MCD+Vit. C
Body Weight (g)
Initial 265 ± 25 241 ± 20 251 ± 25 259 ± 21 242 ± 31
Final 310 ± 28 212 ± 21 * 276 ± 19
† 298 ± 25
† 261 ± 23
†
Liver index (%) 3.01 ± 0.07 3.52 ± 0.09 * 3.09 ± 0.06
† 3.11 ± 0.08
† 3.27 ± 0.21
†
Serum
Albumin (g/dL) 3.27 ± 0.22 3.33 ± 0.16 3.17 ± 0.21 3.01 ± 0.11 3.41 ± 0.25
FBG (mM) 6.11 ± 0.18 11.91 ± 0.28 * 8.55 ± 0.18
† 8.85 ± 0.21
† 9.77 ± 0.23
†
Total Cholesterol (mmol/L) 3.41 ± 0.19 5.55 ± 0.32 * 3.81 ± 0.14
† 3.68 ± 0.18
† 4.29 ± 0.24
†
HDL-C (mmol/L) 2.21 ± 0.05 1.67 ± 0.06 * 2.81 ± 0.11
† 3.04 ± 0.14
† 2.36 ± 0.09
†
LDL-C (mmol/L) 0.91 ± 0.06 1.49 ± 0.18 * 1.11 ± 0.08
† 0.94 ± 0.06
† 1.16 ± 0.07
†
AST (U/L) 110.33 ± 5.23 177.12 ± 11.23 * 145.22 ± 8.33
† 139.72 ± 12.98
† 127.61 ± 14.53
†
ALT (U/L) 67.32 ± 4.34 100.98 ± 9.22 * 86.17 ± 6.31
† 80.11 ± 8.59
† 76.07 ± 6.21
†
ALP (U/L) 872.42 ± 71.25 1849.53 ± 89.21 * 1221.38 ± 65.29
† 1134.15 ± 53.91
† 1378.42 ± 72.78
†
GGT (U/L) 9.61 ± 1.31 13.55 ± 1.18 * 10.85 ± 1.68
† 10.09 ± 1.11
† 10.37 ± 1.98
†
Liver
CAT (U) 2.65 ± 0.07 2.25 ± 0.09 * 2.78 ± 0.11
† 3.23 ± 0.14
† 2.91 ± 0.12
†
SOD (U) 4.45 ± 0.16 3.38 ± 0.18 * 4.62 ± 0.21
† 4.27 ± 0.16
† 4.09 ± 0.21
†
TBARS (nmol/mg liver protein) 0.34 ± 0.04 0.72 ± 0.05 * 0.52 ± 0.03
† 0.48 ± 0.06
† 0.45 ± 0.07
†
PCO (nmol/mg liver protein) 1.41 ± 0.09 2.39 ± 0.11 * 1.94 ± 0.13
† 2.07 ± 0.09
† 1.81 ± 0.05
†
Data are presented as means ± SD (n = 6) of triplicate measurements of each sample. * P < .05 compared to control.
† P < .05 compared to NASH group.
Table 2 Histopathological findings of liver tissue.
Control NASH MCD+EUK-8 MCD+EUK-134 MCD+Vit.C
(n = 5) (n = 5) (n = 5) (n = 5) (n = 5)
Steatosis (%)
Grade 0 100 - 80 80 60
Grade 1 - - 20 20 40
Grade 2 - 100 - - -
Ballooning (%)
Grade 0 100 - 20 20 20
Grade 1 - - 80 80 80
Grade 2 - 100 - - -
Inflammation (%)
Grade 0 100 - 80 80 80
Grade 1 - - 20 20 20
Grade 2 - 100 - - -
Fibrosis - - - - -
All specimens were evaluated blindly by an expert pathologist, according to the scoring system proposed by Kleiner et al. [18]. MCD: methionie and choline
deficient diet.
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change among different groups of rats after eight weeks
of the treatments. The sera levels of FBG, cholesterol
and LDL-C significantly increased among the NASH
group relative to the normal healthy rats by almost 95%,
63% and 63%, respectively, whereas the HDL-C choles-
terol levels significantly decreased by 24% among the
NASH group rats. The FBG levels were significantly
reduced by EUK-8, EUK-134 and vitamin C treatments
by about 55%, 50% and 35%. The cholesterol concentra-
tion was also reduced among the MCD rats under the
effects of EUK-8, EUK-134 and vitamin C by 79%, 83%,
and 65%, respectively. A significant elevation, however,
was observed in the HDL-C level among the MCD rats
treated with EUK-8, EUK-134 and vitamin C (by 51%,
62% and 31%, respectively), while the LDL-C concentra-
tion significantly decreased by 43%, 61% and 36%,
respectively.
Sera hepatic enzymes
In the NASH group, the activities of ALT, AST, ALP
and GGT were significantly increased by 50%, 61%,
112% and 41%, respectively, relative to the control
(Table 1). In the EUK-8 treated MCD rats, the activities
of the aforementioned enzymes significantly reduced by
22%, 28%, 72% and 26%, respectively. Similar results
were obtained for EUK-134 (31%, 33%, 82% and 34%,
respectively). In the vitamin C-treated MCD rats, the
activities of these enzymes were reduced by 36%, 44%,
53% and 32%, respectively.
Hepatic markers of oxidative stress
First, we measured the effects of induced oxidative stress
on the extent of hepatic lipid peroxidation and protein
carbonylation, which were assessed in terms of TBARS
and PCO contents. The results indicated that MCD diet
i n c r e a s e dT B A R Sa n dP C Ol e v e l sb y 1 1 2 %a n d7 1 % ,
Figure 2 Histological evaluation of rats’ livers. Photographs of tissues after Hematoxylin-eosin (A-E) or Masson trichrome staining (F).
Original magnifications ×100. (A) Normal liver histology of a rat fed the standard diet. (B) MCD-fed diet (NASH group) showing ballooning
degeneration, pericentral macrovesicular steatosis and lobular inflammation. (C) group MCD-fed diet + EUK-8 showing normal architecture
with neither steatosis nor inflammation. (D) group MCD-fed diet + EUK-134 showing normal architecture with neither steatosis nor
inflammation. (E) group MCD-fed diet + Vitamin C showing normal architecture, focal macrovesicular steatosis and no inflammation. No
evidences of drug toxicity have been seen in all drug treated MCD-fed group. (F) No significant fibrosis is detected in MCD-fed group. MCD:
methionine and choline deficient diet.
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sured the same factors among the antioxidant (EUK-8,
EUK-134 and vitamin C) -treated rats. Our data indi-
cated that the extents of lipid peroxidation decreased by
57%, 69%, 77% and that of protein carbonylation was
suppressed by 32%, 23%, 42%, respectively (Table 1).
Hepatic antioxidant enzymes
As indicated in Table 1, the hepatic catalase (CAT) and
SOD activities were decreased by 15% and 26%, respec-
tively among rats with NASH compared to normal
healthy rats. On the other hand, the liver CAT and
SOD activities were augmented among the EUK-8,
EUK-134 and vitamin C - treated rats, relative to the
NASH group, by 20%, 37%, 25% and 28%, 20%, 16%,
respectively.
Discussion
To date, no effective therapy has been proposed for
patients with NASH, the progressive stage of NAFLD
[23]. The prevalence of NASH is estimated to be around
3.5-5% amongst Americans [23] and about 3.3% for Ira-
nians [24]. It has been proposed that over-production of
mitochondrial and cytoplasmic superoxide anion, the
precursor of reactive oxygen species (ROS), has a pivotal
role in NASH development [25]. Oxidative stress
increases lipid peroxidation and activates kupffer cells
leading to production of inflammatory cytokines, such
as TNF-a and IL-6 [25]. Therefore, antioxidant thera-
peutic approaches might be beneficial to NASH patients.
In this context, we assessed the relative effects of two
Mn-salen complexes (in comparison to vitamin C) on
NASH in MCD-fed rats. In the current study, steatohe-
patitis was induced by a MCD diet. MCD diet causes
weight loss, oxidative stress, lipid peroxidation and pro-
tein oxidation [25]. Our findings demonstrated, for the
first time, that EUK-8 and EUK-134 supplementation
reduced NASH-induced abnormalities without adverse
effects on rat’s liver. It has been indicated that MCD
diet suppressed hepatic SCD-1 (stearoyl-coenzyme A
desaturase-1) gene, augmented fatty acid catabolism,
increased energy expenditure, decreased adipose tissue
mass, caused liver injury and induced a catabolic state
by hepatic inflammation which caused loss of body
weight [26,27]. In agreement with previous studies, our
results showed that the MCD feeding led to weight loss.
However, the application of this study to obesity-related
NASH is limited by the fact that the metabolic derange-
ments induced by MCD diet might only represent a
unique form of lipodystrophy, with significant weight
loss in combination with hepatic steatosis [26]. In addi-
tion, it has been shown that antioxidants have anti-
inflammatory effects [28]. Furthermore, in this study,
the liver pathological assessments of MCD fed rats
showed that MCD-induced inflammatory damage were
attenuated in Mn-salen complexes. Apparently, the ben-
eficial effect of Mn-salen complexes (as known catalytic
antioxidants) on weight gain is related to their anti-
inflammatory activity.
Our results revealed that MCD diet significantly
enhanced the sera levels of AST, ALT, ALP and GGT,
indicating considerable hepatocellular injury. Antioxi-
dant (EUK-8, EUK-134 and/or vitamin C) treatments
significantly reduced the sera activities of these enzymes,
implying the hepatoprotective effects of EUK-8, EUK-
134 and vitamin C against the harmful effects of MCD
diet. These findings are in good agreement with Laurent
et al. results [25] who showed that SOD mimics reduced
the sera abnormalities in ob/ob mice. Furthermore,
treatments with either EUK-8 or EUK-134 significantly
lowered hepatic lipid peroxidation, PCO production and
inflammation in MCD-fed rats, further confirming the
anti-free radical activity of these compounds.
Administration of Mn-salen complexes to NASH rats
not only suppressed the hepatic lipid peroxidation and
protein oxidation, but also significantly increased the
activity of antioxidant enzymes. It has been reported
that superoxide anion and lipid peroxides inhibit cata-
lase and SOD activities [29]. In the present study, we
observed a decrease in the catalase and SOD activities
in NASH rats compared to normal healthy rats. This
observation is in agreement with the results published
by Koruk et al. [30]. The products of lipid peroxidation
have the ability to react with amino acid residues of
antioxidant enzymes (catalase and SOD), leading to
their inactivation. Suppression of lipid peroxidation by
free-radical scavengers, such as antioxidants, might
account for higher catalase and SOD activities among
the drug - treated rats.
It has been demonstrated that NASH is associated
with elevated levels of plasma cholesterol, triglycerides
and LDL-C. In our study, the Mn-salen complexes
exhibited significant hypolipidemic and hypocholestero-
lemic activities. The elevated level of LDL-C significantly
reduced among rats with NASH following treatments
with EUK-8 and EUK-134. This might be due to the
antioxidant property of Mn-salen complexes and also
due to the increased level of HDL-C, which is capable
of inhibiting the LDL-C peroxidation and retarding the
LDL-C accumulation. Remarkably, serum HDL-C level
increased more than 50% both in the EUK-8 and EUK-
134 treated NASH rats. HDL-C as a multifunctional
lipoprotein, possess antioxidant and anti-inflammatory
activities. The HDL-C antioxidant activity depends on
different factors such as its chemical composition and
the presence of associated enzymes such as paraoxonase
1 (PON1). The hydrolytic inactivation of LDL-C-oxidiz-
ing lipid peroxides by PON1 makes it a key player in
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C, as an anti-inflammatory agent, restricts expression of
pro-inflammatory cytokines such as tumor necrosis fac-
tor-a (TNF-a) and inhibits activation of nuclear factor
kappa B (NF-kB) by interrupting a sphingosine kinase
signaling pathway [32,33]. In addition, expression of the
transforming growth factor (TGF)-b2, a cytokine with
anti-inflammatory properties, is regulated by HDL-C
[33]. Our results showed that MCD diet has a hypergly-
cemic effect which is reduced by administration of the
Mn-salen complexes. It has been previously demon-
strated that hyperglycemia promotes inflammatory
responses through increasing mitochondrial superoxide
production (activation of NF-kB and PKC) [34]. Consid-
ering these assumptions, the observed anti-inflammatory
effects of the Mn-salen complexes might be due to their
hypolipidemic and hypoglycemic properties.
Conclusion
In conclusion, our findings clearly showed that EUK-8
and EUK-134 have hepatoprotective, hypolipidemic,
hypocholesterolimic and hypoglycemic effects on MCD-
fed rats. These activities were comparable to that of
vitamin C, as a natural antioxidant. Thus, the results of
this investigation might provide an insight into further
application of Mn-salen complexes for human clinical
studies for treatment of NASH. However, further inves-
tigations, regarding dose, bioavailability, metabolism, in
vivo accumulation and the relevant cytotoxicity are
required before moving toward clinical phase of
investigation.
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